Abbvie Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Nov 29, 2022 / 03:55PM GMT
Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst

All right. Welcome, everyone. This is Gavin Clark-Gartner and Josh Schimmer from the Evercore ISI biotech research team, and we're very happy to be here with the AbbVie team. Full house, we have Rob Michael, who is the Vice Chairman and President; Jeff Stewart, Chief Commercial Officer; Tom Hudson, SVP of R&D and the Chief Scientific Officer; Scott Reents, Chief Financial Officer; and Roopal Thakkar, who's the VP of Regulatory Affairs and R&D Quality Assurance. Thanks for joining us, guys. So we only have 20 minutes today for our fire side. So we're going to dive right into Q&A.

Questions and Answers:

Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst

And maybe a good place to start is with the Humira biosimilars. So recently, we saw that Optum is putting other biosimilars at parity to Humira. Do you expect more plans to manage biosimilars this way?

Jeffrey Ryan Stewart<
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot